Cancer Survivors Likely to Change Rx Drug Use for Financial Reasons

This article originally appeared here.
Share this content:
Cancer Survivors Likely to Change Rx Drug Use for Financial Reasons
Cancer Survivors Likely to Change Rx Drug Use for Financial Reasons

WEDNESDAY, Feb. 22, 2017 (HealthDay News) -- Nonelderly cancer survivors are more likely to report changes in prescription drug use for financial reasons than individuals without a cancer history, according to a study published online Feb. 20 in Cancer.

Zhiyuan Zheng, Ph.D., from the American Cancer Society in Atlanta, and colleagues identified adults who reported ever having been told they had cancer (8,931 survivors) and 126,287 individuals without a cancer history from the 2011 to 2014 National Health Interview Survey. The authors assessed changes in prescription drug use, including skipping medication doses, taking less medicine, delaying filling a prescription, asking for lower cost medication, buying prescription drugs from abroad, and using alternative treatments for financial reasons.

The researchers found that among nonelderly individuals, compared to those without a cancer history, recently diagnosed and previously diagnosed cancer survivors were more likely to report any change in prescription drug use for financial reasons (31.6 and 27.9, respectively, versus 21.4 percent), with the excess percentage changes for individual measures varying from 3.5 to 9.9 percent and from 2.6 to 2.7 percent among previously and recently diagnosed survivors, respectively (P < 0.01). The rates of changes in prescription drug use for financial reasons were comparable for elderly cancer survivors and those without a cancer history.

"Nonelderly cancer survivors are particularly vulnerable to changes in prescription drug use for financial reasons, suggesting that targeted efforts are needed," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Single-Payer Health System Bill Moves Forward in California

Single-Payer Health System Bill Moves Forward in California

Not yet clear where money for the single-payer system would come from

Regorafenib Approved for Hepatocellular Carcinoma

Regorafenib Approved for Hepatocellular Carcinoma

It is the first approved treatment for HCC in almost a decade

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Rates of worsening low in patients receiving aflibercept, bevacizumab, or ranibizumab

is free, fast, and customized just for you!

Already a member?

Sign In Now »